Please use this identifier to cite or link to this item:
Appears in Collections:Psychology Journal Articles
Peer Review Status: Refereed
Title: Advanced manufacturing, formulation and microencapsulation of therapeutic phages
Author(s): Malik, Danish J
Goncalves-Ribeiro, Henrique
Goldschmitt, Dirk
Collin, Joe
Belkhiri, Aouatif
Fernandes, Diogo
Weichert, Henry
Kirpichnikova, Anna
Contact Email:
Keywords: phage delivery
upstream and downstream processing
phage therapy
Issue Date: Nov-2023
Date Deposited: 27-Oct-2023
Citation: Malik DJ, Goncalves-Ribeiro H, Goldschmitt D, Collin J, Belkhiri A, Fernandes D, Weichert H & Kirpichnikova A (2023) Advanced manufacturing, formulation and microencapsulation of therapeutic phages. <i>Clinical Infectious Diseases</i>, 77 (Supplement 5), pp. S370-S383.
Abstract: Manufacturing and formulation of stable, high purity and high dose bacteriophage drug products suitable for clinical usage would benefit from improved process monitoring and control of critical process parameters that affect product quality attributes. Chemistry, Manufacturing and Controls (CMC) for both upstream (USP) and downstream processes (DSP) need mapping of critical process parameters (CPP) and linking these to critical quality attributes (CQA) to ensure quality and consistency of phage drug substance (DS) and drug product (DP) development. Single-use technologies are increasingly becoming the go-to manufacturing option with benefits both for phage bioprocess development at the engineering run research stage and for final manufacture of the phage drug substance. Future phage drug products under clinical development will benefit from implementation of process analytical technologies (PAT) for better process monitoring and control. These are increasingly being used to improve process robustness (to reduce batch-to-batch variability) and productivity (yielding high phage titres). Precise delivery of stable phage drug products that are suitably formulated as liquids, gels, solid-oral dosage forms etc., could significantly enhance efficacy of phage therapy outcomes. Pre-clinical development of phage drug products must include at an early stage of development, considerations for their formulation including their characterisation of physiochemical properties (size, charge etc.), buffer pH and osmolality, compatibility with regulatory approved excipients, storage stability (packaging, temperature, humidity etc.), ease of application, patient compliance, ease of manufacturability using scalable manufacturing unit operations, cost, and regulatory requirements.
DOI Link: 10.1093/cid/ciad555
Rights: This is a pre-copyedited, author-produced PDF of an article accepted for publication in Clinical Infectious Diseases following peer review. The version of record Danish J Malik, Henrique Goncalves-Ribeiro, Dirk GoldSchmitt, Joe Collin, Aouatif Belkhiri, Diogo Fernandes, Henry Weichert, Anya Kirpichnikova, Advanced Manufacturing, Formulation and Microencapsulation of Therapeutic Phages, Clinical Infectious Diseases, Volume 77, Issue Supplement_5, 1 November 2023, Pages S370–S383 is available online at:
Licence URL(s):

Files in This Item:
File Description SizeFormat 
Manuscript revised after review highlighted copy.pdfFulltext - Accepted Version323.13 kBAdobe PDFUnder Embargo until 2024-11-03    Request a copy

Note: If any of the files in this item are currently embargoed, you can request a copy directly from the author by clicking the padlock icon above. However, this facility is dependent on the depositor still being contactable at their original email address.

This item is protected by original copyright

Items in the Repository are protected by copyright, with all rights reserved, unless otherwise indicated.

The metadata of the records in the Repository are available under the CC0 public domain dedication: No Rights Reserved

If you believe that any material held in STORRE infringes copyright, please contact providing details and we will remove the Work from public display in STORRE and investigate your claim.